Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.46 |
| ▸ | NPY1R | P25929 | 7/20 | 0.46 |
| ▸ | NPY2R | P49146 | 5/20 | 0.46 |
| ▸ | FAP | Q12884 | 5/20 | 0.43 |
| ▸ | FURIN | P09958 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943152 | 0.94 | FAP (0.47) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL24520454 | 0.94 | FAP (0.47) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL29307971 | 0.91 | FAP (0.41) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL21649698 | 0.88 | FURIN (0.44) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL22336596 | 0.88 | FURIN (0.44) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL16273832 | 0.88 | FAP (0.49) | FAPFURIN | |
| SCHEMBL27432486 | 0.88 | FAP (0.46) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL22952275 | 0.88 | FAP (0.44) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL16266214 | 0.88 | FAP (0.44) | NPY4RNPY5RNPY1RNPY2RFAP | |
| SCHEMBL21416485 | 0.88 | FAP (0.44) | NPY4RNPY5RNPY1RNPY2RFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803002-B2 | Anti-wall teichoic antibodies and conjugates | Genentench, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | NPY4R 4262/4885NPY5R 3485/4885NPY1R 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.